Results 91 to 100 of about 12,469 (206)

Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.

, 2003
We analyzed survival rates, neurologic function, and prognostic factors for 118 consecutive patients with acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy (PML) treated with highly active antiretroviral therapy ...
De Miguel, Verónica, Rubio García, Rafael, Berenguer, Juan   +2 more
core   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

, 2011
Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS associated with the JC virus.
Foley, J. F., Olsson, T., R. Gold, S. Richman, Cadavid, D., T. Olsson, D. Cadavid, Richman, S., C. Bozic, L. Kappos, J. F. Foley, Kappos, L., Vermersch, P., Bozic, C., P. Vermersch, Gold, R.   +15 more
core   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

A Representative Survey of M.S. Patients on Attitudes toward the Benefits and Risks of Drug Therapy

Background: Although M.S. patients face significant trade-offs between risks and benefits of drug therapy, little is known of their attitudes toward these risks and benefits.
Calfee, John E.
core  

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Clinical and immunologic effects of maraviroc in progressive multifocal leukoencephalopathy

, 2015
Progressive multifocal leukoencephalopathy (PML) is a rare but generally fatal disease due to JC virus (JCV) reactivation, mainly occurring in immunosuppressed patients.(1) Therapeutic options are limited to blocking glial cell infection by mirtazapine ...
Middel, Ananja, van Lelyveld, Steven F. L., Arends, Joop E., Hoepelman, Andy I. M., Frijns, Catharina J. M., Otto, Sigrid, Tesselaar, Kiki, Schuurman, Rob   +7 more
core   +1 more source

Diagnostic delay in progressive multifocal leukoencephalopathy

, 2016
We investigated delay in diagnosing progressive multifocal leukoencephalopathy (PML). The median time from initial symptom to diagnosis was 74 days (range 1–1643) in 111 PML patients seen at our institution from 1993 to 2015.
Ngo, Long, Koralnik, Igor J., Miskin, Dhanashri P.   +2 more
core   +1 more source

Progressive multifocal leukoencephalopathy in a lung transplant recipient

Clinical Case Reports
Key Clinical Message Progressive multifocal leukoencephalopathy (PML) is a rare and fatal demyelinating disease of the central nervous system (CNS). The case we describe highlights the importance of considering a diagnosis of PML early (
Jason Sakizadeh, Michael J. Davis, Lauren Fontana   +2 more
doaj   +1 more source